不同剂量丙种球蛋白治疗川崎病的疗效的Meta分析

陈婧; 马彬; 林丽星; 薛一鸣

PDF(944 KB)

中国当代儿科杂志 ›› 2011, Vol. 13 ›› Issue (8) : 638-643.

论著·临床研究

不同剂量丙种球蛋白治疗川崎病的疗效的Meta分析

陈婧，马彬，林丽星，薛一鸣

作者信息 +

Treatment of Kawasaki disease by different doses of immunoglobulin: a Mata analysis of therapeutic effects

CHEN Jing, MA Bin, LIN Li-Xing, XUE Yi-Ming

Author information +

文章历史 +

摘要

目的：评价不同剂量丙种球蛋白治疗川崎病的临床疗效和安全性。方法：计算机检索PubMed、EMBASE、Cochrane图书馆、CNKI、VIP和万方等数据库。纳入不同剂量丙种球蛋白治疗川崎病的随机对照试验（RCT）研究，并对其进行质量评价，用Rev Man 5.0软件进行Meta分析。结果：纳入28个RCT共2596例患儿。Meta分析显示：① 1 g/(kg?d)×1~2 d vs 2 g/(kg?d)单次：在急性和亚急性期、6个月、1年的冠状动脉异常、不良反应方面及退热时间方面差异无统计学意义；② 1 g/(kg?d)×1~2 d vs 400 mg/(kg?d)×4~5 d：1 g/(kg?d)×1~2 d 组比400 mg/(kg?d)×4~5 d组退热时间短，差异有统计学意义;在急性期、6个月冠状动脉异常、不良反应方面两组差异均无统计学意义；③ 2 g/(kg?d)单次 vs 400 mg/(kg?d)×4~5 d：2 g/(kg?d) 单次给药在急性期、6个月冠状动脉损伤的发生比率低、退热时间短,差异有统计学意义，在亚急性期、1年冠状动脉异常、不良反应方面差异无统计学意义。结论：丙种球蛋白1 g/(kg?d)×1~2 d组与2 g/(kg?d)单次组疗效相似。而1 g/(kg?d)×1~2 d组与2 g/(kg?d)单次组在退热时间方面均优于400 mg/(kg?d)×4~5 d组。

Abstract

OBJECTIVE: To assess the therapeutic effects and safety of different doses of immunoglobulin in the treatment of Kawasaki disease. METHODS: The papers related to the treatment of Kawasaki disease were electronically searched in the databases of PubMed, EMBASE, Cochrane Library, CNKI, VIP and Wanfang. Randomized clinical trials (RCT) on the treatment of Kawasaki disease with different doses of immunoglobulin were included and assessed for quality. A Mata analysis was performed by RevMan 5.0. RESULTS: Twenty-eight RCTs involved 2596 cases were included. The results of Meta analysis showed that there were no significant differences in the incidences of coronary artery injuries at various phases, adverse effects and fever disappearance time between the immunoglobulin treatment groups at the doses of 1 g/(kg?d) for 1-2 days and 2 g/(kg?d) for single use. The fever disappearance time in the immunoglobulin treatment group at the dose of 1 g/(kg?d) for 1-2 days was significantly shorter than that in the immunoglobulin treatment group at the dose of 400 mg/(kg?d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the acute phase and 6 months after treatment and adverse effects between the two groups. The incidence of coronary artery injuries at the acute phase and 6 months was lower and the fever disappearance time was shorter in the immunoglobulin treatment group at the dose of 2 g/(kg?d) for single use than those in the immunoglobulin treatment group at the dose of 400 mg/(kg?d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the subacute phase and 12 months after treatment and adverse effects between the two groups. CONCLUSIONS: There are similar therapeutic effects for Kawasaki disease between the immunoglobulin treatment groups at the doses of 1 g/(kg?d) for 1-2 days and 2 g/(kg?d) for single use. The fever disappearance time in the two groups is shorter than that in the treatment group at the dose of 400 mg /(kg?d) for 4-5 days.

导出引用

陈婧，马彬，林丽星，薛一鸣. 不同剂量丙种球蛋白治疗川崎病的疗效的Meta分析[J]. 中国当代儿科杂志. 2011, 13(8): 638-643

CHEN Jing, MA Bin, LIN Li-Xing, XUE Yi-Ming. Treatment of Kawasaki disease by different doses of immunoglobulin: a Mata analysis of therapeutic effects[J]. Chinese Journal of Contemporary Pediatrics. 2011, 13(8): 638-643

中图分类号： R725.4

参考文献

［1］Kim DS. Kawasaki disease［J］. Yonsei Med J, 2006, 47(6)：759-772.

［2］Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome［J］. J Pediatr, 1993, 122(4)：538-542.

［3］Cha S, Yoon M, Ahn Y, Han M, Yoon KL. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease［J］. J Korean Med Sci, 2008, 23(4)：718-722.

［4］Liang CM, Lee PC, Hwang BT, Lu JH, Wang PY, Lien CH, et al. Comparison of different types and regimens of intravenous immune globulin (IVIG) in patients with Kawasaki disease［J］. Acta Cardiol Sin, 2004, 20(1):15-20.

［5］Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome［J］. Rheumatol Int, 2010, 30(6)：841-846.

［6］Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yoshihara T, Nishiki T, et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease［J］. Eur J Pediatr, 2007,166(6): 565-571.

［7］杜忠东,赵地,杜军保,鲁珊,衣京梅,侯安存,等.不同静脉丙种球蛋白给药方法治疗川崎病的效果比较［J］. 中华医学杂志,2007,87(44):3119-3121.

［8］Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease［J］. Recent Pat Cardiovasc Drug Discov, 2008, 3(2): 141-144.

［9］Shulman ST. Kawasaki disease and IVIG: what's going on here? Immunotherapy with intravenous immunoglobulins ［M］. San Diego：Academic Press, 1991: 261-268.

［10］Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 ［updated February 2008］［DB/OL］. The Cochrane Collaboration, 2008. Available at www. Cochrane-handbook org.

［11］Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome［J］. N Engl J Med, 1991, 324(23): 1633-1639.

［12］覃丽君,王宏伟,胡秀芬,刘清军,施虹,隈远祥,等. 静脉注射不同剂量丙种球蛋白治疗川崎病的临床研究［J］. 中华儿科杂志, 2006,44（12）：891-895.

［13］Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness［J］. Pediatr Int, 1999, 41(1):1-7.

［14］Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome［J］. Clin Pediatr (Phila), 2002, 41(8): 597-601.

［15］陈步青,施文忠. 中等剂量丙种球蛋白治疗川崎病的临床观察［J］. 浙江临床医学, 2006,8(3):308.

［16］邓美英. 丙种球蛋白治疗川崎病两种方案的疗效比较［J］. 国际医药卫生导报, 2005,11(2):33-34.

［17］付济南，陈海萍.不同剂量静脉丙种球蛋白给药方法治疗川崎病的疗效比较［J］. 中国现代药物应用,2010,4(7):121-122.

［18］郭丽. 静注不同剂量丙种球蛋白治疗川崎病的疗效观察及护理体会［J］. 中国临床实用医学, 2009,3(7):116-117.

［19］何旭香,张茜,李锦燕. 不同剂量静脉免疫球蛋白治疗川崎病65例疗效观察［J］. 福建医药杂志, 2003,25(2):49-50.

［20］何洲. 两种方法静脉滴注丙种球蛋白治疗急性期川崎病疗效比较［J］. 河北医药, 2004，26(4):323-323.

［21］李湘玲,廖英. 单剂量丙种球蛋白治疗川崎病33例疗效分析［J］. 赣南医学院学报, 2008,28(1):36-37.

［22］李建国. 两种方法静脉注射丙种球蛋白治疗川崎病的疗效观察［J］. 实用临床医学, 2009,10(12):60-61.

［23］廖均,何开静. 不同剂量丙种球蛋白静脉注射治疗川崎病的临床研究［J］.中国医疗前沿,2007,2(22):8-9.

［24］刘雪梅. 静滴免疫球蛋白治疗川崎病的剂量探讨［J］. 山东医药，2000,40(8):23-24.

［25］刘天鉴. 静注丙种球蛋白治疗川崎病的疗效观察［J］. 现代中西医结合杂志, 2004, 13(4)：451.

［26］刘明,程均,罗勤. 用两种方法静脉注射丙种球蛋白治疗川崎病患儿的疗效对比观察［J］. 中国优生与遗传杂志, 2009,17(2):117-118.

［27］陆击修,郑志龙. 静脉注射免疫球蛋白治疗川崎病的疗效分析［J］. 青海医药杂志, 2003,33(5):16-18.

［28］彭楚明,肖琴,陈友林,苏咏. 静脉注射不同剂量免疫球蛋白治疗川崎病的临床疗效观察［J］. 南华大学学报(医学版), 2001,29(6):581-583.

［29］阮兢,蔡仕俊,林茹珠,邓向红,陈简，李明. 两种丙种球蛋白方案治疗川崎病疗效比较［J］. 青岛医药卫生, 2006,38(3):175-176.

［30］阮健,杨华彬, 阮兢,何晓玲. 两种大剂量丙种球蛋白方案治疗小儿川崎病的疗效比较［J］. 实用药物与临床, 2005,8(3):48-49.

［31］阮仙利,项如莲,梁国安,芦洪萍. 不同剂量IVIG对川崎病患儿CD_4~+/CD_8~+的影响［J］. 儿科药学杂志, 2003,9(3):18-19.

［32］严平. 不同剂量静脉注射丙种球蛋白治疗川崎病的疗效观察［J］. 社区医学杂志, 2007,5(23):11.

［33］杨海霞,郑敏翠. 用两种方法静脉注射丙种球蛋白治疗川崎病的疗效对比观察［J］. 中国当代儿科杂志, 2004,6(1):57-58.

［34］姚小花. 不同剂量静脉注射丙种球蛋白治疗川崎病64例疗效观察［J］. 中国社区医师（医学专业半月刊）, 2009,11(213):68-69.

［35］袁玉方,蒯文霞. 丙种球蛋白在小儿川崎病中的应用研究［J］. 山西医药杂志, 2009,38(4):365-366.

［36］岳爱红,田庆玲,历红. 静脉注射丙种球蛋白治疗小儿川崎病56例疗效观察［J］. 临床荟萃, 2006,21(13): 962-963.

［37］张玉清. 两种方案大剂量静脉丙种球蛋白治疗川崎病［J］. 四川医学, 2007,28(7):801-802.

［38］张卫华. 不同剂量丙种球蛋白治疗川崎病118例疗效分析［J］. 实用医学进修杂志, 2008, 36(2):117-120.

［39］Mofi M, Miyamae T, Imgawa T, Katakura S, Kimura K, Yokota S. Meta-analysis of the results of intravenous gamma-globulin treatment of coronary artery lesions in Kawasaki disease［J］. Mod Rheumatol, 2004,14(5): 361-366.